ArticleActa cirurgica brasileira2026
Evaluation of the osteoconductive potential of Croton lechleri sap associated with collagen or wax-based carriers in critical-size bone defects in rat calvaria.
Article in Acta cirurgica brasileira, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate bone repair in critical size calvarial defects (8 mm) in rats treated with Croton lechleri sap (dragon's blood sap, DBS) combined with Hemospon® and Alveolex®.
methodsSeventy-two Wistar rats were divided into six groups: G1, Hemospon®; G2, Hemospon® + DBS; G3, Alveolex®; G4, Alveolex® + DBS; C-, blood clot; and C+, LuminaCoat® membrane. At 30 and 60 days, specimens were submitted to histological and histomorphometric analysis, quantifying newly formed bone, residual biomaterial, and connective tissue.
resultsNo statistically significant differences were observed among groups in new bone formation. At 30 days, G3 presented the highest mean of newly formed bone (18.6 ± 6.8%), followed by G2 (16.0 ± 4.8%). G4 presented the lowest mean (10.7 ± 1.3%). At 60 days, C+ exhibited the greatest bone formation (29.5 ± 21.0%). G2 showed the highest biomaterial persistence at 30 (19.4 ± 0.6%) and 60 days (17.4 ± 3.9%). G3 presented the lowest connective tissue density at 30 days (49.2 ± 6.3%); C+ exhibited the lowest value at 60 days (38.9 ± 18.1%).
conclusionHemospon® associated with DBS proved to be the most promising osteoconductive system, favoring biomaterial persistence and reducing fibrogenesis, whereas the association with Alveolex® was less favorable. The DBS shows biotechnological potential, but its stabilizing effect on the scaffold requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.